Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LPCN Lipocine Inc
- Stocks
- Healthcare
- NASDAQ: LPCN
Price (delayed)
$3.2328
Market cap
$17.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1
Enterprise value
$13.94M
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN
Highlights
Lipocine's EPS has increased by 41% YoY
LPCN's net income is up by 40% YoY
The quick ratio has decreased by 8% YoY but it has increased by 6% from the previous quarter
LPCN's revenue has dropped by 67% since the previous quarter and by 22% year-on-year
The gross profit has dropped by 67% since the previous quarter and by 22% year-on-year
Key stats
What are the main financial stats of LPCN
Market
Valuations
Earnings
Shares outstanding
5.35M
Market cap
$17.3M
Enterprise value
$13.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
4.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.79
Revenue
$3.67M
Gross profit
$3.67M
Operating income
-$6.47M
Net income
-$5.37M
EBIT
-$5.37M
EBITDA
-$5.32M
Free cash flow
-$5.69M
Per share
Balance sheet
Liquidity
EPS
-$1
EPS diluted
-$1.02
Free cash flow per share
-$1.06
Book value per share
$3.59
Revenue per share
$0.69
TBVPS
$3.83
Total assets
$20.5M
Total liabilities
$1.3M
Debt
$0
Equity
$19.2M
Working capital
$19.03M
Debt to equity
0
Current ratio
15.64
Quick ratio
15.17
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
-144.8%
Gross margin
100%
Net margin
-146.1%
Operating margin
-176%
Return on assets
-24.8%
Return on equity
-26.7%
Return on invested capital
-34.8%
Return on capital employed
-28%
Return on sales
-146.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPCN stock price
How has the Lipocine stock price performed over time
Intraday
-2.04%
1 week
-9.19%
1 month
14.23%
1 year
-33.34%
YTD
-33.75%
QTD
1.66%
Financial performance
How have Lipocine's revenue and profit performed over time
Revenue
$3.67M
Gross profit
$3.67M
Operating income
-$6.47M
Net income
-$5.37M
Gross margin
100%
Net margin
-146.1%
LPCN's revenue has dropped by 67% since the previous quarter and by 22% year-on-year
The gross profit has dropped by 67% since the previous quarter and by 22% year-on-year
LPCN's net income is up by 40% YoY
The company's operating income rose by 38% YoY
Price vs fundamentals
How does LPCN's price correlate with its fundamentals
Growth
What is Lipocine's growth rate over time
Valuation
What is Lipocine stock price valuation
P/E
N/A
P/B
0.9
P/S
4.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.79
Lipocine's EPS has increased by 41% YoY
The P/B is 59% less than the 5-year quarterly average of 2.2 and 36% less than the last 4 quarters average of 1.4
Lipocine's equity has decreased by 20% YoY and by 9% QoQ
LPCN's revenue has dropped by 67% since the previous quarter and by 22% year-on-year
Efficiency
How efficient is Lipocine business performance
Lipocine's ROE has increased by 29% YoY
LPCN's ROA is up by 28% year-on-year
The ROIC has grown by 24% YoY
Lipocine's return on sales has increased by 23% YoY
Dividends
What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPCN.
Financial health
How did Lipocine financials performed over time
Lipocine's total assets has decreased by 19% YoY and by 9% QoQ
LPCN's total liabilities is down by 14% since the previous quarter and by 13% year-on-year
LPCN's debt is 100% smaller than its equity
Lipocine's equity has decreased by 20% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.